<< Вернуться к списку статей журнала

Том 15 №1 2013 год - Нефрология и диализ

Лечение вирусных гепатитов у реципиентов почечногоаллотрансплантата (Обзор литературы)

Ватазин А.В. Прокопенко Е.И. Зулькарнаев А.Б. Кантария Р.О. Артемов Д.В.

Аннотация: В обзоре литературы освещено современное представление отечественных и иностранных авторов об эффективности и безопасности применения различных схем лечения вирусных гепатитов у реципиентов почечного трансплантата. Также приводится краткий обзор возможностей метода каскаднойплазмофильтрации при лечении гепатита.

Для цитирования: Ватазин А.В., Прокопенко Е.И., Зулькарнаев А.Б., Кантария Р.О., Артемов Д.В. Лечение вирусных гепатитов у реципиентов почечногоаллотрансплантата (Обзор литературы). Нефрология и диализ. 2013. 15(1):54-58. doi:

Весь текст

Ключевые слова: renal transplantation, hepatitis «C», hepatitis «B», the renal allograft, double-filtration plasmapheresis, трансплантация почки, гепатит С, гепатит В, почечный аллотрансплантат, каскадная плазмофильтрация

Список литературы:

1. Прокопенко Е.И., Ватазин А.В., Щербакова Е.О. Инфекционные осложнения после трансплантации почки Руководство по инфекционным болезням. М.: ИПО «УНикитскихворот», 2010. 296 с.
2. Ahn H.J., Kim M.S., Kim Y.S. et al. Clinical outcome of renal transplantation in patients with positivepre-transplanthepatitis B surface antigen // J. Med. Virol. 2007. Vol. 79. № 11. P. 1655–1663.
3. Baid-Agrawal S.,Pascual M., Moradpour D. et al. Hepatitis C virus infection in haemodialysis and kidney transplant patients // Rev. Med. Virol. 2008. Vol. 18. № 2. P. 97–115.
4. Braks R.E., Ganne-Carrie N., Fontaine H. et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin // World J. Gastroenterol. 2007. Vol. 13. № 42. P. 5648–5653.
5. Cardoso A.C., Moucari R., Figueiredo-Mendes C. et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis // J Hepatol. 2010. Vol. 52. № 5. P. 652–657.
6. Di Martino V., Crouzet, J., Hillon P. et al. Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: a propensity-adjusted analysis // J. Viral. Hepat. 2011. Vol. 18. № 7. P. 493–505.
7. Domínguez-Gil B., Morales J.M. Transplantation in the patient with hepatitis C // Transpl Int. 2009. Vol. 22. № 12. P. 1117–1131.
8. Einollahi B., Alavian S.M. Hepatitis C virus infection and kidney transplantation: a review for clinicians // Iran J Kidney Dis. 2010. Vol. 4. № 1. P. 1–8.
9. El-Farrash M.A., Aly H.H., Watashi K. et al. In vitro infection of immortalized primary hepatocytes by HCV genotype 4a and inhibition of virus replication by cyclosporine // Microbiol. Immunol. 2007. Vol. 51. № 1. P. 127–133.
10. Fabrizi F., Bromberg J., Elli A. et al. Review article: hepatitis C virus and calcineurin inhibition after renal transplantation // Aliment. Pharmacol. Ther. 2005. Vol. 22. № 8. Р. 657–666.
11. Fabrizi F., Bunnapradist S., Martin P. Treatment of hepatitis C in potential kidney and heart transplant patients // Clin. Liver Dis. 2005. Vol. 9. № 3. P. 487–503.
12. Fabrizi F., Lunghi G., Ganeshan S.V. et al. Hepatitis C virus infection and the dialysis patient // Semin Dial. 2007. Vol. 20. № 5. P. 416–422.
13. Fabrizi F., Poordad F.F., Martin P. Hepatitis C infection and the patient with end-stage renal disease // Hepatology. 2002. Vol. 36. № 1. P. 3–10.
14. Fischer G., Gallay P., Hopkins S. et al. Cyclophilin inhibitors for the treatment of HCV infection // Curr. Opin. Investig. Drugs. 2010. Vol. 11. № 8. P. 911–918.
15. Fujiwara K., Kaneko S., Kakumu S. et al. Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load // Hepatol. Res. 2007. Vol. 37. № 9. P. 701–710.
16. Gordon C.E., Uhlig K.,Lau J. et al. Interferon for hepatitis C virus in hemodialysis an individual patient meta-analysis of factors associated with sustained virological response // Clin. J. Am. Soc. Nephrol. 2009. Vol. 4. № 9. P. 1449–1458.
17. Gordon C.E., Uhlig K.,Lau J. et al. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms // Am. J Kidney Dis. 2008. Vol. 51. № 2. P. 263–277.
18. Gwak G.Y., Huh W., Lee D.H. et al. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy // Transplant Proc. 2007. Vol. 39. № 10. P. 3121–3126.
19. Hanafusa N., Kondo Y., Suzuki M. et al. Double filtration plasmapheresis can decrease factor XIII Activity // Ther. Apher. Dial. 2007. Vol. 11. № 3. P. 165–170.
20. Hanafusa N., Satonaka H., Doi K. et al. Virus removal and eradication by modified double filtration plasmapheresis decreases factor XIII levels // Ther. Apher. Dial. 2010. Vol. 14. № 3. P. 287–291.
21. Henry S.D., Metselaar H.J., Lonsdale R.C. et al.Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha // Gastroenterology. 2006. Vol. 131. № 5. P. 1452–1462.
22. Hu T.H., Tsai M.C., Chien Y.S. et al. A novel experience of antiviral therapy for chronic hepatitis B in renal transplant recipients. // AntivirTher. 2012. Vol. 17. № 4. P. 745–753.
23. Iacobellis A., Perri F., Valvano M.R. et al. Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis // Clin. Gastroenterol. Hepatol. 2011. Vol. 9. № 3. P. 249–253.
24. Ishikawa T., Higuchi K., Kubota T. et al. Complete early virological response was highly achieved by double filtration plasmapheresis plus IFN-beta induction therapy for HCV-1b patients with relapse or no response after previous IFN therapy // Ther. Apher. Dial. 2011. Vol. 15. № 4. P. 400–405.
25. Jeon J.W., Shin H.P., Lee J.I. et al. Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B // Dig Dis Sci. 2012. Vol. 57. № 5. P. 1358–1365.
26. Kahraman A., Witzke O., Scherag A. et al. Impact of immunosuppressive therapy on hepatitis C infection after renal transplantation // Clin. Nephrol. 2011. Vol. 75. № 1. P. 16–25.
27. Kalia H., Lopez P.M., Martin P. Treatment of HCV in patients with renal failure // Arch. Med. Res. 2007. Vol. 38. № 6. P. 628–633.
28. Kamar N., Ribes D., Izopet J., Rostaing L. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant // Transplantation. 2006. Vol. 82. № 7. Р. 853–856.
29. Kamar N., Huart A., Tack I. Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients // Clin Nephrol. 2009. Vol. 71. № 1. P. 36–42.
30. Kaneko S., Sata M., Ide T. et al. Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C // Hepatol. Res. 2010. Vol. 40. № 11. P. 1072–1081.
31. Kes P., Basic-Jukic N. Hepatitis C in dialysed patients what is the current optimal treatment? // Kidney Blood Press Res. 2007. Vol. 30. № 3. P. 156–161.
32. Kim E., Ko H.H., Yoshida E.M. Treatment issues surrounding hepatitis C in renal transplantation: a review // Ann. Hepatol. 2011. Vol. 10. № 1. P. 5–14.
33. Kim S.R., Imoto S., Kudo M. et al. Double-filtration plasmapheresis plus IFN for HCV-1b patients with non-sustained virological response to previous combination therapy: early viral dynamics // Intervirology. 2010. Vol. 53. № 1. P. 44–48.
34. Kondo Y., Ueno Y., Wakui Y. et al. Rapid reduction of hepatitis C virus-Core protein in the peripheral blood improve the immunological response in chronic hepatitis C patients // Hepatol Res. 2011. Vol. 41. № 12. P. 1153–1168.
35. Konishi I., Horiike N., Michitaka K. et al. Renal transplant recipient with chronic hepatitis C who obtained sustained viral response after interferon-beta therapy // Intern. Med. 2004. Vol. 43. № 10. P. 931–934.
36. Lampertico P., Viganò M., Facchetti F. et al. Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B // Nephrol Dial Transplant. 2011. Vol. 26. № 6. P. 2037–2041.
37. Levent F. Double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C // Hepatol. Res. 2011. Vol. 41. № 2. P. 197.
38. Li M.W., Hou W., Wo J.E. et al. Characterof HBV (hepatitis Bvirus) polymer asegenert M204V/I and rtL180M mutation in patients with lamivud in eresistance // J. Zhejiang Univ. Sci. B. 2005. Vol. 6. № 7. P. 664–667.
39. Manga Sahin G., Sahin S., Kantarci G., Ergin H. Impact of hepatitis C virus infection on patient and graft survival in kidney transplantation // Transplant Proc. 2006. Vol. 38. № 2. P. 499–501.
40. Martin P., Fabrizi F. Hepatitis C virus and kidney disease // J Hepatol. 2008. Vol. 49. № 4. P. 613–624.
41. Matos C.A., Perez R.M., Lemos L.B. et al. Factors associated with the intensity of liver fibrosis in renal transplant patients with hepatitis B virus infection // Eur. J Gastroenterol. Hepatol. 2007. Vol. 19. № 8. P. 653–657.
42. Morales J.M., Marcén R., Andres A. et al. Renal transplantation in patients with hepatitis C virus antibody. A long national experience // NDT Plus. 2010. Vol. 3. Suppl. 2. P. 41–46.
43. Mousa D.H., Abdalla A.H., Al-Shoail G. et al. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C // Transplant Proc. 2004. Vol. 36. № 6. P. 1831–1834.
44. Namba T., Shiba R., Yamamoto T. et al. Successful treatment of HCV-related cryoglobulinemic glomerulonephritis with double-filtration plasmapheresis and interferon combination therapy // Clin. Exp. Nephrol. 2010. Vol. 14. № 4. P. 372–376.
45. Nanmoku K., Imaizumi R., Tojimbara T. et al. Effects of immunosuppressants on the progression of hepatitis C in hepatitis C virus-positive renal transplantation and the usefulness of interferon therapy // Transplant. Proc. 2008. Vol. 40. № 7. Р. 2382–2385.
46. Ohara T., Oteki T., Suzuki T. et al. Efficacy of double filtration plasmapheresis with pegylated interferon/ribavirin therapy for intractable chronic hepatitis C patients and hepatitis C patients with combined liver cirrhosis by HBV, leading to early viral elimination // Hepatogastroenterology. 2011. Vol. 58. № 105. P. 133–136.
47. Park K.S., Yang W.S., Han D.J. et al. Long-term impact of prophylactic antiviral treatment in Hepatitis B surface antigenpositive renal allograft recipients // ClinNephrol. 2012. Vol. 78. № 4. P. 303–311.
48. Perrillo R.P., Hann H.W., Schiff E. et al. Extended treatment withlamivudineand adefovirdipivoxil in chronichepatitisB patients withlamivudineresistance // Hepatol. Int. 2011. Vol. 5. № 2. P. 654–663.
49. Rapti I.N., Hadziyannis S.J. Treatment of special populations with chronic hepatitis B infection // Expert Rev Gastroenterol Hepatol. 2011. Vol. 5. № 3. P. 323–339.
50. Sharma R.K., Bansal S.B., Gupta A. et al. Chronic hepatitis C virus infection in renal transplant: treatment and outcome // Clin. Transplant. 2006. Vol. 20. № 6. P. 677–683.
51. Takada Y., Ito T., Ueda Y. et al. Effects of double-filtration plasmapheresis combined with interferon plus ribavirin for recurrent hepatitis C after living donor liver transplantation // Liver Transpl. 2008. Vol. 14. № 7. P. 1044–1047.
52. Tang I.Y., Walzer N., Aggarwal N. et al. Management of the kidney transplant patient with chronic hepatitis C infection // Int. J. Nephrol. 2011. Vol. 2011. P. 245823.
53. Taniguchi M., Furukawa H., Shimamura T. et al. Impact of double-filtration plasmapheresis in combination with interferon and ribavirin in living donor liver transplant recipients withhepatitis C // Transplantation. 2006. Vol. 81. № 12. P. 1747–1749.
54. Torre F., Giannini E.G., Basso M. et al. Initial high dose oflamivudinedelays the appearance of viralresistancein chronichepatitisB patients // J. Gastrointestin. Liver. Dis. 2011. Vol. 20. № 1. P. 47–50.
55. Trapero-Marugán M., Mendoza J., Chaparro M. et al. Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin // World J Gastroenterol. 2011. Vol. 17. № 4. P. 493–498.
56. Tsai M.C., Chen Y.T., Chien Y.S. et al. Hepatitis B virus infection and renal transplantation // World J Gastroenterol. 2010. Vol. 16. № 31. P. 3878–3887.
57. Tullis R.H., Duffin R.P., Ichim T.E. et al. Modeling hepatitis C virus therapies combining drugs and lectin affinity plasmapheresis // Blood Purif. 2010. Vol. 29. № 2. P. 210–215.
58. Vallet-Pichard A., Fontaine H., Mallet V., Pol S. VIRAL hepatitis in solid organ transplantation other than liver // J Hepatol. 2011. Vol. 55. № 2. P. 474–482.
59. Wong J.B., Davis G.L., McHutchison J.G. et al. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C // Am J Gastroenterol. 2003. Vol. 98. № 11. P. 2354–2362.
60. Yamashita T., Arai K., Sakai A. et al. Virological effects and safety of combined double filtration plasmapheresis (DFPP) and interferon therapy in patients with chronichepatitis C: A preliminary study // Hepatol. Res. 2006. Vol. 36. № 3. P. 167–175.
61. Yap D.Y., Tang C.S., Yung S. et al. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments // Transplantation. 2010. Vol. 90. № 3. P. 325–330.

Другие статьи по теме

• Трансплантация почки у реципиентов с онкологическим поражением собственных почек
• Особенности суточного профиля индекса аугментации у подростков после трансплантации почки
• Опыт применения микофенолата натрия при трансплантации почки (промежуточные результаты 12 месячной мультицентровой открытой наблюдательной программы изучения безопасности, переносимости и эффективности препарата у реципиентов почечного трансплантата)
• Особенности респираторной тактики при двусторонней интерстициальной пневмонии на фоне хронического отторжения